2015’s Worst Clinical Failures – Nasdaq.com

Additionally, there’s still a chance that obeticholic acid posts better results in the larger ongoing U.S. phase 3 study than it did in this smaller Japanese phase 2 trial. Tying it together The sheer number of trial failures makes drugmakers some of the riskiest stocks to buy. Risk of trial failure can be lowered by diversifying across stocks and focusing on drugmakers with late-stage clinical trials underway, but since two of these failures occurred in phase 3 studies, there’s no guarantee or magic formula for success. Investors must be willing to accept the risk that is inherent in this industry if they want to benefit from potential rewards associated with successful, game-changing medicines. The next billion-dollar iSecret The world’s biggest tech company forgot to show you something at its recent event, but a few Wall Street analysts and the Fool didn’t miss a beat: There’s a small company that’s powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here . Interactive Charts Default Setting Please note that once you make your selection, it will apply to all future visits to NASDAQ.com.